Sunday, April 18, 2021

Global CRO acquires Derbyshire-based Retrogenix

Retrogenix, the Derbyshire-based early-stage contract research organisation (CRO) providing specialised bioanalytical services, has been acquired by Charles River Laboratories.

Charles River is a global CRO providing drug discovery and development services. The acquisition further strengthens its integrated end-to-end solution for therapeutic antibody, and cell and gene therapy discovery and development.

Employing 18,000 professionals at over 100 sites worldwide, the company has participated in the development of 80% of the drugs approved by the FDA over the last 3 years.

Wilbert Frieling, Corporate Senior Vice President, Global Discovery Services, Charles River, said: “We are delighted to add Retrogenix’s highly effective cell screening service to Charles River’s integrated offering.

“Coupled with our comprehensive drug discovery service portfolio, Retrogenix’s novel cell microarray technology and library of plasma membrane and secreted protein clones will allow us to support our clients by informing early drug discovery efforts and providing preclinical safety assurance.”

Retrogenix will continue to operate from its High Peak facilities, and there will be no changes to its workforce.

Dr Jim Freeth, Co-Founder, Retrogenix, said: “Joining Charles River is a very exciting step for Retrogenix, allowing us to integrate into a comprehensive service supporting the entire CRO development pipeline. With Charles River’s support, we are looking forward to accelerating our growth and technological development.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemic having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £33.60 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.

Latest news

Related news

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.